Cite
MLA Citation
Andrew E. Sloan et al.. “141 Phase I Trial of Genetically Modified Hematopoietic Progenitor Cells Facilitate Bone Marrow Chemoprotection and Enabling TMZ/O6BG Dose Escalation Resulting in Improved Survival.” Neurosurgery, vol. 63, n.d., p. 157. http://access.bl.uk/ark:/81055/vdc_100130427691.0x000041